Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by bluebird bio, Inc.

< Previous 1 2 3 Next >
bluebird bio to Present at the 42nd Annual J.P. Morgan Healthcare Conference
From bluebird bio, Inc.
Via Business Wire
Tickers BLUE
bluebird bio, Inc. Announces Pricing of $125 Million Public Offering of Common Stock
From bluebird bio, Inc.
Via Business Wire
Tickers BLUE
bluebird bio, Inc. Announces Proposed Public Offering of Common Stock
From bluebird bio, Inc.
Via Business Wire
Tickers BLUE
Long-Term Data Presented at ASH Support beti-cel as a Potentially Curative Gene Therapy for β-Thalassemia Patients Who Require Regular Transfusions Through Achievement of Durable Transfusion Independence and Normal or Near-Normal Adult Hb Levels
From bluebird bio, Inc.
Via Business Wire
Tickers BLUE
Long-term Follow-up Data From bluebird’s Gene Therapy Program in Sickle Cell Disease Support Durable, Potentially Curative Benefits Through Stable Production of Anti-Sickling Adult Hemoglobin and Resolution of Vaso-Occlusive Events
From bluebird bio, Inc.
Via Business Wire
Tickers BLUE
bluebird bio Details Plans for the Commercial Launch of LYFGENIA™ Gene Therapy for Patients Ages 12 and Older with Sickle Cell Disease and a History of Vaso-Occlusive Events
From bluebird bio, Inc.
Via Business Wire
Tickers BLUE
bluebird bio Announces FDA Approval of LYFGENIA™ (lovotibeglogene autotemcel) for Patients Ages 12 and Older with Sickle Cell Disease and a History of Vaso-Occlusive Events
From bluebird bio, Inc.
Via Business Wire
Tickers BLUE
bluebird bio Reports Third Quarter 2023 Financial Results and Highlights Operational Progress
From bluebird bio, Inc.
Via Business Wire
Tickers BLUE
bluebird bio to Present New and Updated Data from Gene Therapy Programs in Sickle Cell Disease and Beta-Thalassemia at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition
From bluebird bio, Inc.
Via Business Wire
Tickers BLUE
bluebird bio Enters into Advance Agreement to Sell Priority Review Voucher, if Granted, for $103 Million
From bluebird bio, Inc.
Via Business Wire
Tickers BLUE
bluebird bio to Host Third Quarter 2023 Financial Results Conference Call
From bluebird bio, Inc.
Via Business Wire
Tickers BLUE
bluebird bio Announces September Investor Events
From bluebird bio, Inc.
Via Business Wire
Tickers BLUE
bluebird bio Confirms That FDA Has Communicated That Advisory Committee Meeting Will Not Be Scheduled for lovo-cel Gene Therapy for Sickle Cell Disease
From bluebird bio, Inc.
Via Business Wire
Tickers BLUE
bluebird bio Reports Second Quarter 2023 Financial Results and Highlights Operational Progress
From bluebird bio, Inc.
Via Business Wire
Tickers BLUE
bluebird bio to Host Second Quarter 2023 Financial Results Conference Call and Provide Commercial Update
From bluebird bio, Inc.
Via Business Wire
Tickers BLUE
bluebird bio Announces FDA Priority Review of the Biologics License Application for lovotibeglogene autotemcel (lovo-cel) for Patients with Sickle Cell Disease (SCD) 12 years and Older with a History of Vaso-Occlusive Events
From bluebird bio, Inc.
Via Business Wire
Tickers BLUE
bluebird bio Reports First Quarter 2023 Financial Results and Highlights Operational Progress
From bluebird bio, Inc.
Via Business Wire
Tickers BLUE
bluebird bio Submits Biologics License Application (BLA) to FDA for lovotibeglogene autotemcel (lovo-cel) for Patients with Sickle Cell Disease (SCD) 12 years and Older with a History of Vaso-Occlusive Events
From bluebird bio, Inc.
Via Business Wire
Tickers BLUE
bluebird bio Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Operational Progress
From bluebird bio, Inc.
Via Business Wire
Tickers BLUE
bluebird bio, Inc. Announces Pricing of $120 Million Public Offering of Common Stock
From bluebird bio, Inc.
Via Business Wire
Tickers BLUE
bluebird bio, Inc. Announces Proposed Public Offering of Common Stock
From bluebird bio, Inc.
Via Business Wire
Tickers BLUE
bluebird bio Provides Update on Commercial Launch Progress, Program Milestones and 2023 Financial Outlook Ahead of Company Presentation at 41st Annual J.P. Morgan Healthcare Conference
From bluebird bio, Inc.
Via Business Wire
Tickers BLUE
bluebird bio Sells Second Priority Review Voucher for $95 Million
From bluebird bio, Inc.
Via Business Wire
Tickers BLUE
bluebird bio to Present at the 41st Annual J.P. Morgan Healthcare Conference
From bluebird bio, Inc.
Via Business Wire
Tickers BLUE
bluebird bio Appoints Joseph Vittiglio, JD, as Chief Business and Legal Officer
From bluebird bio, Inc.
Via Business Wire
Tickers BLUE
FDA Lifts Partial Clinical Hold for bluebird bio’s Sickle Cell Disease (SCD) Studies for Patients Under the Age of 18
From bluebird bio, Inc.
Via Business Wire
Tickers BLUE
bluebird bio Sells Priority Review Voucher for $102 Million
From bluebird bio, Inc.
Via Business Wire
Tickers BLUE
bluebird bio Reports Third Quarter 2022 Financial Results and Highlights Operational Progress
From bluebird bio, Inc.
Via Business Wire
Tickers BLUE
bluebird bio to Present at the 31st Annual Credit Suisse Healthcare Conference
From bluebird bio, Inc.
Via Business Wire
Tickers BLUE
bluebird bio Receives FDA Accelerated Approval for SKYSONA® Gene Therapy for Early, Active Cerebral Adrenoleukodystrophy (CALD)
From bluebird bio, Inc.
Via Business Wire
Tickers BLUE
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.